WebDecember 2, 2024 - Cumberland Pharmaceuticals announced the FDA approval of RediTrex (methotrexate) injection, for the management of patients with severe, active rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis (pJIA), and for symptomatic control of severe, recalcitrant, disabling psoriasis in adults. Download PDF Web29. sep 2024 · RediTrex treats patients with severe, active rheumatoid arthritis and polyarticular juvenile idiopathic arthritis who have difficulty tolerating or responding to orally delivered MTX. It is also approved for symptomatic control of severe, recalcitrant, disabling psoriasis in adults who are not adequately responsive to other forms of therapy.
210737Orig1s000 210737Orig2s000 LABELING - Food and Drug …
WebREDITREX is a single dose prefilled syringe containing a prescription medicine, methotrexate. Methotrexate is used to: • treat certain adults with severe, active … WebRediTrex contains methotrexate in a sterile, preservative-free, solution in a pre-filled syringe (in a needle safety device) with a 29 gauge ½ inch needle for a single subcutaneous injection. RediTrex solution is yellow in color. RediTrex is available at a concentration of 25 mg/mL to administer the following doses of methotrexate solution: 7.5 mg tab black eyed peas
Label and Warnings 66220-825 Reditrex - ndclist.com
Web17. nov 2024 · RediTrex is FDA approved for patients with severe, active rheumatoid arthritis and polyarticular juvenile idiopathic arthritis who have difficulty tolerating or responding … WebRasuvo [prescribing information]. Chicago, IL: Medac Pharma; March 2024. 8. Reditrex [prescribing information]. Nashville, TN: Cumberland Pharmaceuticals; November 2024. Revision History ; Type of Revision Summary of Changes Approval Date ; Annual Revision No criteria changes. 12/21/2024 Web19. nov 2024 · 5. ( 1) Cumberland Pharmaceuticals has announced the launch of RediTrex, a new line of methotrexate prefilled syringes for the treatment of polyarticular juvenile idiopathic arthritis (pJIA), active rheumatoid arthritis, and severe psoriasis in the U.S. Eligible pJIA patients must be intolerant to or show an inadequate response to first-line ... tab book club